
Medical HAL Obtained marketing clearance from U.S. FDA (2017/12/17)



Page 2 - Yohei Suzuki requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 807 requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR 803); good manufacturing reaction requirements as set forth in the quality everage (OC) regulation (21 CFR 803); good 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR 931 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act) (21 CFR 931 820); manutacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part and Part of Adverse events under the MDR regulation (21 CFR Part of Part Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803). nlease on to http://www.fda.oov/MedicalDevices/Safety/RenortaProblem/default.htm for the CDR Hy. 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's oos), picase go to nuprowww.ma.gov/memcanzevices/Sanety/Reportarioon
Office of Surveillance and Biometrics/Division of Postmarket Surveillance. For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice

(https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Lo Consumer Education (DICE) to ask a question about (1-800-638-2041 or 3

Therapeutic effects of the device was acknowledged by the FDA, stating that the device is designed to improve ambulation upon completion of HAL gait training intervention

Medical HAL became the only medical device that is classified under the combination of these two categories,

- Neurological Devices §21 CFR 882.5050
- Physical Medicine Devices §21 CFR 890.3480

FDA also changed the definition of §21 CFR 890.3480!

FDA Product Classification 21 CFR 890.3480 2017/12/11 (Before marketing approval)



Major difference between HAL and other devices

	HAL for Medical Use	Other Devices
Classification Name	Powered Lower Extremity Exoskeleton (primary) Biofeedback Device	Powered Lower Extremity Exoskeleton
Regulation Number	Physical Medicine Devices 21 CFR 890.3480 (primary) Neurological Devices 21 CFR 882.5050	Physical Medicine Devices 21 CFR 890.3480
Product Code	PHL (primary) HCC	PHL
Indications for Use	Improvement ambulation upon completion of HAL gait training intervention	Perform ambulation while the device is worn
level of spinal cord injury	C4~L5	T4~L5 (ReWalk), T4~L5 (Indigo), C7~L5 (Ekso) [Ekso can be used for stroke]
Method of Control	Mainly <u>controlled by <mark>Bioelectrical signals</mark></u> at knee and hip extensor and flex muscles	Remote control worn on write to change modes; postal cues for stepping *Feature of predicate devices and other devices with a product code of PHL
Clinical Studies	The clinical result suggest both statistically and clinically significant improvement without wearing the HAL device	Safe to use and enables the user to perform ambulatory functions better while the device is worn

Business Development in USA

Joint venture established with one of the largest rehabilitation hospital group, "Brooks Rehabilitation" on establishment of a center for Cybernic Treatment with HAL (2018/02)



- 45,000 patients p.a.
- one of the largest inpatient rehab hospitals in USA 32 outpatient clinics
- clinical research centers for stroke, spinal cord injury, etc.



left: Yoshiyuki Sankai, President & CEO, CYBERDYNE INC. right: Michael Spigel, President & COO, Brooks Rehabilitation